Clinical Trials | November 30, 2025
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Poviztra is a second brand of Wegovy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
